Summit X LLC’s Biolase, Inc. BIOL Stock Holding History

Summit X LLC’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4	Closed	-$7K	–	273
2021 Q2	$7K	Hold	4	–	–	﹤0.01%	264
2021 Q1	$8K	Buy	+4	New	+$9.83K	﹤0.01%	261

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit X LLC's BIOL Position: Q3 2021 in Review

Summit X LLC sold out of Biolase, Inc. (BIOL) in Q3 2021, closing a stake of 4 shares — an estimated $7K sold.

Summit X LLC first reported a position in BIOL in Q1 2021 and held it in 2 quarters. The position peaked at $8K in Q1 2021. 38 funds tracked by Wall St. Rank hold BIOL as of Q3 2021.

Summit X LLC reported no remaining Biolase, Inc. position as of Q3 2021 after selling out during the quarter.
Summit X LLC sold 4 Biolase, Inc. shares in Q3 2021, an estimated $7K.
Summit X LLC first reported a position in Biolase, Inc. in Q1 2021 and held it in 2 quarters.
Summit X LLC's Biolase, Inc. position peaked at $8K in Q1 2021.
38 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2021.

Based on Summit X LLC's 13F filing for Q3 2021, filed 19 Oct 2021.